Integrated network pharmacology demonstrates ZhiXiaoSanZheng affects kidney injury in diabetic kidney disease, suggesting a new treatment approach.
ZXSZF alleviates podocyte injury in DKD and its renoprotective effects are associated with modulation of ferroptosis-related processes involving the NRF2/SLC7A11/GPX4 pathway. The present study provides experimental evidence for the mechanistic basis of ZXSZF and supports its potential role as a complementary therapeutic option in DKD management.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: